Share This Page

GOP prepares for House vote on medical research bill

| Tuesday, Nov. 29, 2016, 10:06 p.m.

WASHINGTON — Republicans and Democrats put finishing touches Tuesday on a $6.3 billion medical research bill as GOP leaders prepared to try pushing the measure through the lame-duck Congress by next week. The White House said it backs the measure, all but ensuring its approval.

While Democrats and consumer groups were unhappy with parts of the legislation, it contained enough accomplishments for both sides that passage seemed likely. Government drug approvals would be accelerated, there would be more money for biomedical research — including on cancer, a priority for the White House and Vice President Joe Biden — and there would be added funds for battling abuse of addictive drugs like opioids, a growing problem that plagues red and blue states alike.

In a letter to lawmakers, White House officials said the administration strongly supports the legislation and praised almost every aspect of it. It cited some problems, such as a need for more money to implement some of its requirements, but said, “This legislation offers advances in health that far outweigh these concerns.”

The House was planning to consider the 996-page package Wednesday, with Senate action expected next week.

“It's a very important and attractive piece of legislation. I anticipate a big vote,” said Sen. Lamar Alexander, R-Tenn., who chairs the Senate Health Committee.

In eleventh-hour talks, both sides said they had agreed to remove language that would have exempted companies from publicly reporting education-related gifts to doctors, such as textbooks. Firms must report many payments they give physicians, which critics say encourage doctors to prescribe products made by those companies.

Democrats had wanted stronger language to assure that the money the legislation makes available would actually be provided by future Congresses. They were also unhappy with provisions making it easier to get government approval to prescribe existing drugs for new uses, and with the measure's cuts in President Obama's health care law and other programs, which would take effect immediately.

But with Donald Trump replacing a more supportive Obama in the White House in just two months, Democratic leverage to demand changes was limited.

In remarks Tuesday to the Senate, Minority Leader Harry Reid, D-Nev., said there is “some angst” among Democrats about the bill and said he was expecting it to be changed, but was not specific.

The bill was drawing populist attacks from two of the Senate's most liberal members, Elizabeth Warren, D-Mass., and Bernie Sanders, I-Vt.

Sanders said Congress must “stand up to the world's biggest pharmaceutical companies, not give them more handouts.” In a fierce Senate speech Monday, Warren called the bill “corrupt” and “very, very dangerous.”

TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.